Stocktoria
Vor Biopharma Inc. VOR
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-05
Vor Biopharma Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D expense | $321.5M | $93.3M | $94.3M | $64.5M | $47.5M | $31.6M |
| Operating income | -$371.6M | -$121.2M | -$126.0M | -$93.4M | -$69.0M | -$43.4M |
| Net income | -$696.0M | -$116.9M | -$117.9M | -$92.1M | -$68.9M | -$43.3M |
| EPS (diluted) | $-70.50 | $-34.03 | $-1.75 | $-2.33 | $-2.10 | — |
| Operating cash flow | -$142.7M | -$99.7M | -$100.3M | -$85.1M | -$69.1M | -$36.3M |
| Free cash flow | -$143.7M | -$99.9M | -$101.4M | -$93.6M | -$73.0M | -$40.5M |
| Cash & equivalents | $396.5M | $81.9M | $31.4M | $57.7M | $119.8M | $48.5M |
| Total assets | $464.1M | $142.9M | $198.1M | $299.4M | $242.6M | $75.9M |
| Total liabilities | $628.4M | $46.2M | $47.4M | $48.8M | $26.3M | $27.6M |
| Shareholders' equity | -$164.3M | $96.7M | $150.7M | $250.6M | $216.3M | -$59.1M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.